MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice

Q: What is the clinical evidence from this study?

Study design: Review. Population: Metabolic dysfunction-associated steatotic liver disease (MASLD). Intervention: Fibrosis-based risk stratification and cardiometabolic therapies (e.g., resmetirom, semaglutide, SGLT2 inhibitors, lifestyle modification). Primary outcome: Cardiovascular events and mortality in MASLD.

Sainan Li; Michel Toutoungy; Janvi Patel; Indira Bhavsar-Burke; Lisa B. VanWagner

doi:10.1007/s11906-026-01380-9

August 1, 2026Current Hypertension ReportsOpen Access

MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice

View Full Paper

Ask AI

Bookmark

Share

Key result

MASLD linked to ~50% higher cardiovascular event risk, increasing to ~2.5-fold with advanced fibrosis.

Key Points

To review current evidence on the epidemiology, pathophysiologic mechanisms, biomarkers, and therapies linking metabolic dysfunction-associated steatotic liver disease to cardiovascular disease risk.
Synthesized clinical and epidemiological evidence regarding metabolic dysfunction-associated steatotic liver disease (MASLD), evaluating diagnostic markers, noninvasive fibrosis assessment tools, and cardiometabolic interventions.
MASLD affects 38% of adults globally, with cardiovascular disease serving as the leading cause of death across disease stages (10-year cumulative incidence of 8.1%).
Advanced fibrosis confers up to an approximately 2.5-fold increase in cardiovascular events beyond traditional risk factors, while noninvasive scores such as FIB-4 and liver stiffness predict cardiovascular mortality.
Dual-acting agents like semaglutide and resmetirom show combined hepatic and cardiometabolic benefits, though definitive evidence confirming that histologic improvement reduces cardiovascular events remains uncertain.

Structured PICO

P

Population

Adults globally with metabolic dysfunction-associated steatotic liver disease (MASLD), affecting 38% of the adult population and defined by hepatic steatosis with at least one cardiometabolic risk factor.

I

Intervention

Noninvasive fibrosis risk stratification (FIB-4, VCTE, ELF, MRE) and lifestyle/pharmacologic therapies across the hepatic-cardiorenal axis (weight loss, bariatric surgery, Mediterranean diet, resmetirom, GLP-1 receptor agonists such as semaglutide, dual GIP/GLP-1 agonists such as tirzepatide, SGLT2 inhibitors, statins, and RAAS inhibitors).

O

Outcome

Cardiovascular disease events and mortality, MASH resolution, and hepatic fibrosis regression.

Limitations

Fibrosis-based risk stratification remains absent from standard cardiovascular risk models despite its prognostic value.
Whether improving liver disease or hepatic fibrosis independently reduces cardiovascular events has not been definitively established.
Whether improvement in hepatic fibrosis independently reverses cardiovascular disease or reduces cardiovascular events has not been definitively established.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Liver fibrosis stage in MASLD is a powerful independent predictor of cardiovascular mortality that should be used by clinicians as a cardiovascular risk enhancer to guide intensified preventive and dual cardiometabolic-hepatic therapies.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disease. This review summarizes recent advances in epidemiology, pathophysiology, biomarkers, and treatment relevant to cardiovascular risk assessment and management. Fibrosis stage is the strongest independent predictor of cardiovascular outcomes in MASLD, conferring up to a 2.5-fold increase in events beyond traditional risk factors. Noninvasive tools, including Fibrosis-4 (FIB-4) and liver stiffness measurement, also predict cardiovascular mortality. Semaglutide and resmetirom offer dual hepatic and cardiometabolic benefits. MASLD affects 38% of adults globally, and cardiovascular disease (CVD) is the leading cause of death across disease stages. Fibrosis-based risk stratification remains absent from standard cardiovascular risk models despite its prognostic value. Therapies with combined liver and cardiovascular benefits are promising, but whether improving liver disease reduces cardiovascular events remains uncertain.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2026) conducted a review in Metabolic dysfunction-associated steatotic liver disease (MASLD). Fibrosis-based risk stratification and cardiometabolic therapies (e.g., resmetirom, semaglutide, SGLT2 inhibitors, lifestyle modification) was evaluated on Cardiovascular events and mortality in MASLD. MASLD confers an approximately 1.5-fold higher risk of cardiovascular events, rising up to 2.5-fold in advanced liver fibrosis beyond traditional risk factors.

synapsesocial.com/papers/6a70405975942ff7265e54e9 https://doi.org/10.1007/s11906-026-01380-9

View Full Paper

Ask AI

Bookmark

Share

MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading